Dorit Trudler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dorit Trudler has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Stuart A. Lipton
The Scripps Research Institute
7 shared publications Nima Dolatabadi
Neurodegeneration New Medicines Center The Scripps Research Institute La Jolla California USA
5 shared publicationsMaria Talantova
Neurodegeneration New Medicines Center and Department of Molecular Medicine, The Scripps Research Institute, La Jolla, USA
3 shared publicationsNicholas J. Schork
Translational Genomics Research Institute, Phoenix, AZ, USA
3 shared publications- Sergio Rodriguez Labra
Department of Chemistry and Department of Molecular Medicine, The Scripps Research Institute (TSRI), La Jolla, CA 92037
3 shared publications Stuart Lipton
Department of Molecular Medicine, Scripps Research Institute, La Jolla, USA
3 shared publications
Latest Publications
- Open Access
- 27 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (17) , e14783
Autophagy Activators Normalize Aberrant Tau Proteostasis and Rescue Synapses in Human Familial Alzheimer's Disease iPSC‐Derived Cortical Organoids
Alzheimer's disease (AD) is the leading cause of dementia worldwide. Nevertheless, its cellular and molecular mechanisms remain incompletely understood, partially due to inadequate disease models. To illuminate early changes in AD, we developed a cerebrocortical organoid (CO) model with improved methodology. Our COs produce excitatory and inhibitory neurons alongside glia, utilizing established isogenic wild‐type and diseased human induced pluripotent stem cells (hiPSCs) carrying heterozygous familial AD mutations in PSEN1 ΔE9 /WT, PSEN1 M146V /WT, or APP Swe /WT. In addition to amyloid‐beta (Aβ) accumulation, the AD COs display time‐progressive loss of monomeric Tau, and accumulation of aggregated high‐molecular‐weight (HMW) phospho(p)‐Tau species (pT181 and pT217). They also exhibit neuronal hyperexcitability reminiscent of early electroencephalography (EEG) clinical findings and synapse loss in AD patient brains. Single‐cell RNA‐sequencing analyses of AD and WT control COs reveal significant divergent molecular abnormalities in excitatory vs. inhibitory neurons, with several pathways being upregulated in one while downregulated in the other, providing insight into AD phenotypes. Finally, we show that chronic dosing with autophagy activators, including a novel mTOR inhibitor‐independent drug candidate, prevents pathologic Aβ and HMW p‐Tau accumulation, normalizes hyperexcitability, and rescues synaptic loss in AD COs. Collectively, our results demonstrate this CO model as a useful platform for assessing early features of familial AD pathogenesis and for testing small‐molecule candidate therapeutics.
- 27 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (17) , e14783
Open AccessAutophagy Activators Normalize Aberrant Tau Proteostasis and Rescue Synapses in Human Familial Alzheimer's Disease iPSC‐Derived Cortical Organoids
Alzheimer's disease (AD) is the leading cause of dementia worldwide. Nevertheless, its cellular and molecular mechanisms remain incompletely understood, partially due to inadequate disease models. To illuminate early changes in AD, we developed a cerebrocortical organoid (CO) model with improved methodology. Our COs produce excitatory and inhibitory neurons alongside glia, utilizing established isogenic wild‐type and diseased human induced pluripotent stem cells (hiPSCs) carrying heterozygous familial AD mutations in PSEN1 ΔE9 /WT, PSEN1 M146V /WT, or APP Swe /WT. In addition to amyloid‐beta (Aβ) accumulation, the AD COs display time‐progressive loss of monomeric Tau, and accumulation of aggregated high‐molecular‐weight (HMW) phospho(p)‐Tau species (pT181 and pT217). They also exhibit neuronal hyperexcitability reminiscent of early electroencephalography (EEG) clinical findings and synapse loss in AD patient brains. Single‐cell RNA‐sequencing analyses of AD and WT control COs reveal significant divergent molecular abnormalities in excitatory vs. inhibitory neurons, with several pathways being upregulated in one while downregulated in the other, providing insight into AD phenotypes. Finally, we show that chronic dosing with autophagy activators, including a novel mTOR inhibitor‐independent drug candidate, prevents pathologic Aβ and HMW p‐Tau accumulation, normalizes hyperexcitability, and rescues synaptic loss in AD COs. Collectively, our results demonstrate this CO model as a useful platform for assessing early features of familial AD pathogenesis and for testing small‐molecule candidate therapeutics.
- Open Access
Autophagy activators normalize aberrant Tau proteostasis and rescue synapses in human familial Alzheimer’s disease iPSC-derived cortical organoids
SUMMARY: Alzheimer’s disease (AD) is the most common form of dementia worldwide. Despite extensive progress, the cellular and molecular mechanisms of AD remain incompletely understood, partially due to inadequate disease models. To illuminate the earliest changes in hereditary (familial) Alzheimer’s disease, we developed an isogenic AD cerebrocortical organoid (CO) model. Our refined methodology produces COs containing excitatory and inhibitory neurons alongside glial cells, utilizing established isogenic wild-type and diseased human induced pluripotent stem cells (hiPSCs) carrying heterozygous familial AD mutations, namely PSEN1 ΔE9/WT , PSEN1 M146V/WT , or APP swe/WT . Our CO model reveals time-progressive accumulation of amyloid beta (Aβ) species, loss of monomeric Tau, and accumulation of aggregated high-molecular-weight (HMW) phospho(p)-Tau species. This is accompanied by neuronal hyperexcitability, as observed in early human AD cases on electroencephalography (EEG), and synapse loss. Single-cell RNA-sequencing analyses reveal significant differences in molecular abnormalities in excitatory vs. inhibitory neurons, helping explain AD clinical phenotypes. Finally, we show that chronic dosing with autophagy activators, including a novel CNS-penetrant mTOR inhibitor-independent drug candidate, normalizes pathologic accumulation of Aβ and HMW p-Tau, normalizes hyperexcitability, and rescues synaptic loss in COs. Collectively, our results demonstrate these COs are a useful human AD model suitable for assessing early features of familial AD etiology and for testing drug candidates that ameliorate or prevent molecular AD phenotypes.
Open AccessAutophagy activators normalize aberrant Tau proteostasis and rescue synapses in human familial Alzheimer’s disease iPSC-derived cortical organoids
SUMMARY: Alzheimer’s disease (AD) is the most common form of dementia worldwide. Despite extensive progress, the cellular and molecular mechanisms of AD remain incompletely understood, partially due to inadequate disease models. To illuminate the earliest changes in hereditary (familial) Alzheimer’s disease, we developed an isogenic AD cerebrocortical organoid (CO) model. Our refined methodology produces COs containing excitatory and inhibitory neurons alongside glial cells, utilizing established isogenic wild-type and diseased human induced pluripotent stem cells (hiPSCs) carrying heterozygous familial AD mutations, namely PSEN1 ΔE9/WT , PSEN1 M146V/WT , or APP swe/WT . Our CO model reveals time-progressive accumulation of amyloid beta (Aβ) species, loss of monomeric Tau, and accumulation of aggregated high-molecular-weight (HMW) phospho(p)-Tau species. This is accompanied by neuronal hyperexcitability, as observed in early human AD cases on electroencephalography (EEG), and synapse loss. Single-cell RNA-sequencing analyses reveal significant differences in molecular abnormalities in excitatory vs. inhibitory neurons, helping explain AD clinical phenotypes. Finally, we show that chronic dosing with autophagy activators, including a novel CNS-penetrant mTOR inhibitor-independent drug candidate, normalizes pathologic accumulation of Aβ and HMW p-Tau, normalizes hyperexcitability, and rescues synaptic loss in COs. Collectively, our results demonstrate these COs are a useful human AD model suitable for assessing early features of familial AD etiology and for testing drug candidates that ameliorate or prevent molecular AD phenotypes.
- Open Access
- 30 September 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (4) , 1479-1496
Dysregulation of miRNA expression and excitation in MEF2C autism patient hiPSC-neurons and cerebral organoids
MEF2C is a critical transcription factor in neurodevelopment, whose loss-of-function mutation in humans results in MEF2C haploinsufficiency syndrome (MHS), a severe form of autism spectrum disorder (ASD)/intellectual disability (ID). Despite prior animal studies of MEF2C heterozygosity to mimic MHS, MHS-specific mutations have not been investigated previously, particularly in a human context as hiPSCs afford. Here, for the first time, we use patient hiPSC-derived cerebrocortical neurons and cerebral organoids to characterize MHS deficits. Unexpectedly, we found that decreased neurogenesis was accompanied by activation of a micro-(mi)RNA-mediated gliogenesis pathway. We also demonstrate network-level hyperexcitability in MHS neurons, as evidenced by excessive synaptic and extrasynaptic activity contributing to excitatory/inhibitory (E/I) imbalance. Notably, the predominantly extrasynaptic (e)NMDA receptor antagonist, NitroSynapsin, corrects this aberrant electrical activity associated with abnormal phenotypes. During neurodevelopment, MEF2C regulates many ASD-associated gene networks, suggesting that treatment of MHS deficits may possibly help other forms of ASD as well.
- 30 September 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (4) , 1479-1496
Open AccessDysregulation of miRNA expression and excitation in MEF2C autism patient hiPSC-neurons and cerebral organoids
MEF2C is a critical transcription factor in neurodevelopment, whose loss-of-function mutation in humans results in MEF2C haploinsufficiency syndrome (MHS), a severe form of autism spectrum disorder (ASD)/intellectual disability (ID). Despite prior animal studies of MEF2C heterozygosity to mimic MHS, MHS-specific mutations have not been investigated previously, particularly in a human context as hiPSCs afford. Here, for the first time, we use patient hiPSC-derived cerebrocortical neurons and cerebral organoids to characterize MHS deficits. Unexpectedly, we found that decreased neurogenesis was accompanied by activation of a micro-(mi)RNA-mediated gliogenesis pathway. We also demonstrate network-level hyperexcitability in MHS neurons, as evidenced by excessive synaptic and extrasynaptic activity contributing to excitatory/inhibitory (E/I) imbalance. Notably, the predominantly extrasynaptic (e)NMDA receptor antagonist, NitroSynapsin, corrects this aberrant electrical activity associated with abnormal phenotypes. During neurodevelopment, MEF2C regulates many ASD-associated gene networks, suggesting that treatment of MHS deficits may possibly help other forms of ASD as well.
- Open Access
- 16 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (50) , eade0764
Mechanistic insight into female predominance in Alzheimer’s disease based on aberrant protein S-nitrosylation of C3
Protein S-nitros(yl)ation (SNO) is a posttranslational modification involved in diverse processes in health and disease and can contribute to synaptic damage in Alzheimer’s disease (AD). To identify SNO proteins in AD brains, we used triaryl phosphine ( SNO TRAP) combined with mass spectrometry (MS). We detected 1449 SNO proteins with 2809 SNO sites, representing a wide range of S-nitrosylated proteins in 40 postmortem AD and non-AD human brains from patients of both sexes. Integrative protein ranking revealed the top 10 increased SNO proteins, including complement component 3 (C3), p62 (SQSTM1), and phospholipase D3. Increased levels of S-nitrosylated C3 were present in female over male AD brains. Mechanistically, we show that formation of SNO-C3 is dependent on falling β-estradiol levels, leading to increased synaptic phagocytosis and thus synapse loss and consequent cognitive decline. Collectively, we demonstrate robust alterations in the S-nitrosoproteome that contribute to AD pathogenesis in a sex-dependent manner.
- 16 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (50) , eade0764
Open AccessMechanistic insight into female predominance in Alzheimer’s disease based on aberrant protein S-nitrosylation of C3
Protein S-nitros(yl)ation (SNO) is a posttranslational modification involved in diverse processes in health and disease and can contribute to synaptic damage in Alzheimer’s disease (AD). To identify SNO proteins in AD brains, we used triaryl phosphine ( SNO TRAP) combined with mass spectrometry (MS). We detected 1449 SNO proteins with 2809 SNO sites, representing a wide range of S-nitrosylated proteins in 40 postmortem AD and non-AD human brains from patients of both sexes. Integrative protein ranking revealed the top 10 increased SNO proteins, including complement component 3 (C3), p62 (SQSTM1), and phospholipase D3. Increased levels of S-nitrosylated C3 were present in female over male AD brains. Mechanistically, we show that formation of SNO-C3 is dependent on falling β-estradiol levels, leading to increased synaptic phagocytosis and thus synapse loss and consequent cognitive decline. Collectively, we demonstrate robust alterations in the S-nitrosoproteome that contribute to AD pathogenesis in a sex-dependent manner.
- 8 April 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 118 (15)
Soluble α-synuclein–antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia
Significance: Release of oligomeric/fibrillar α-synuclein (αSyn) from damaged neurons contributes to neuronal cell death in Parkinson’s disease and other neurodegenerative disorders in part via microglial activation. Here, we show that αSyn activates the NLRP3 inflammasome in human induced pluripotent stem cell (hiPSC)-derived microglia (hiMG) via dual stimulation involving TLR2 engagement and mitochondrial damage. Oligomerized amyloid-β peptide (Aβ), as found in Alzheimer’s disease brains, exacerbates this neuroinflammation. Importantly, we found that misfolded proteins such as αSyn and Aβ, when bound to antibody and presented to hiMG, result in enhanced proinflammatory response of the NLRP3 inflammasome. These findings may have important implications for antibody therapies aimed at depleting misfolded/aggregated proteins from the human brain, as they may paradoxically trigger neuroinflammation in human microglia.
- 8 April 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 118 (15)
Soluble α-synuclein–antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia
Significance: Release of oligomeric/fibrillar α-synuclein (αSyn) from damaged neurons contributes to neuronal cell death in Parkinson’s disease and other neurodegenerative disorders in part via microglial activation. Here, we show that αSyn activates the NLRP3 inflammasome in human induced pluripotent stem cell (hiPSC)-derived microglia (hiMG) via dual stimulation involving TLR2 engagement and mitochondrial damage. Oligomerized amyloid-β peptide (Aβ), as found in Alzheimer’s disease brains, exacerbates this neuroinflammation. Importantly, we found that misfolded proteins such as αSyn and Aβ, when bound to antibody and presented to hiMG, result in enhanced proinflammatory response of the NLRP3 inflammasome. These findings may have important implications for antibody therapies aimed at depleting misfolded/aggregated proteins from the human brain, as they may paradoxically trigger neuroinflammation in human microglia.
- Open Access
- 22 January 2021
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 41 (10) , 2264-2273
α-Synuclein Oligomers Induce Glutamate Release from Astrocytes and Excessive Extrasynaptic NMDAR Activity in Neurons, Thus Contributing to Synapse Loss
Synaptic and neuronal loss are major neuropathological characteristics of Parkinson's disease. Misfolded protein aggregates in the form of Lewy bodies, comprised mainly of α-synuclein (αSyn), are associated with disease progression, and have also been linked to other neurodegenerative diseases, including Lewy body dementia, Alzheimer's disease, and frontotemporal dementia. However, the effects of αSyn and its mechanism of synaptic damage remain incompletely understood. Here, we show that αSyn oligomers induce Ca2+-dependent release of glutamate from astrocytes obtained from male and female mice, and that mice overexpressing αSyn manifest increased tonic release of glutamatein vivo. In turn, this extracellular glutamate activates glutamate receptors, including extrasynaptic NMDARs (eNMDARs), on neurons both in culture and in hippocampal slices of αSyn-overexpressing mice. Additionally, in patch-clamp recording from outside-out patches, we found that oligomerized αSyn can directly activate eNMDARs. In organotypic slices, oligomeric αSyn induces eNMDAR-mediated synaptic loss, which can be reversed by the drug NitroSynapsin. When we expose human induced pluripotent stem cell-derived cerebrocortical neurons to αSyn, we find similar effects. Importantly, the improved NMDAR antagonist NitroSynapsin, which selectively inhibits extrasynaptic over physiological synaptic NMDAR activity, protects synapses from oligomeric αSyn-induced damage in our model systems, thus meriting further study for its therapeutic potential.SIGNIFICANCE STATEMENTLoss of synaptic function and ensuing neuronal loss are associated with disease progression in Parkinson's disease (PD), Lewy body dementia (LBD), and other neurodegenerative diseases. However, the mechanism of synaptic damage remains incompletely understood. α-Synuclein (αSyn) misfolds in PD/LBD, forming Lewy bodies and contributing to disease pathogenesis. Here, we found that misfolded/oligomeric αSyn releases excessive astrocytic glutamate, in turn activating neuronal extrasynaptic NMDA receptors (eNMDARs), thereby contributing to synaptic damage. Additionally, αSyn oligomers directly activate eNMDARs, further contributing to damage. While the FDA-approved drug memantine has been reported to offer some benefit in PD/LBD (Hershey and Coleman-Jackson, 2019), we find that the improved eNMDAR antagonist NitroSynapsin ameliorates αSyn-induced synaptic spine loss, providing potential disease-modifying intervention in PD/LBD.
- 22 January 2021
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 41 (10) , 2264-2273
Open Accessα-Synuclein Oligomers Induce Glutamate Release from Astrocytes and Excessive Extrasynaptic NMDAR Activity in Neurons, Thus Contributing to Synapse Loss
Synaptic and neuronal loss are major neuropathological characteristics of Parkinson's disease. Misfolded protein aggregates in the form of Lewy bodies, comprised mainly of α-synuclein (αSyn), are associated with disease progression, and have also been linked to other neurodegenerative diseases, including Lewy body dementia, Alzheimer's disease, and frontotemporal dementia. However, the effects of αSyn and its mechanism of synaptic damage remain incompletely understood. Here, we show that αSyn oligomers induce Ca2+-dependent release of glutamate from astrocytes obtained from male and female mice, and that mice overexpressing αSyn manifest increased tonic release of glutamatein vivo. In turn, this extracellular glutamate activates glutamate receptors, including extrasynaptic NMDARs (eNMDARs), on neurons both in culture and in hippocampal slices of αSyn-overexpressing mice. Additionally, in patch-clamp recording from outside-out patches, we found that oligomerized αSyn can directly activate eNMDARs. In organotypic slices, oligomeric αSyn induces eNMDAR-mediated synaptic loss, which can be reversed by the drug NitroSynapsin. When we expose human induced pluripotent stem cell-derived cerebrocortical neurons to αSyn, we find similar effects. Importantly, the improved NMDAR antagonist NitroSynapsin, which selectively inhibits extrasynaptic over physiological synaptic NMDAR activity, protects synapses from oligomeric αSyn-induced damage in our model systems, thus meriting further study for its therapeutic potential.SIGNIFICANCE STATEMENTLoss of synaptic function and ensuing neuronal loss are associated with disease progression in Parkinson's disease (PD), Lewy body dementia (LBD), and other neurodegenerative diseases. However, the mechanism of synaptic damage remains incompletely understood. α-Synuclein (αSyn) misfolds in PD/LBD, forming Lewy bodies and contributing to disease pathogenesis. Here, we found that misfolded/oligomeric αSyn releases excessive astrocytic glutamate, in turn activating neuronal extrasynaptic NMDA receptors (eNMDARs), thereby contributing to synaptic damage. Additionally, αSyn oligomers directly activate eNMDARs, further contributing to damage. While the FDA-approved drug memantine has been reported to offer some benefit in PD/LBD (Hershey and Coleman-Jackson, 2019), we find that the improved eNMDAR antagonist NitroSynapsin ameliorates αSyn-induced synaptic spine loss, providing potential disease-modifying intervention in PD/LBD.
- Open Access
- 29 November 2019
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 8
Mechanisms of hyperexcitability in Alzheimer’s disease hiPSC-derived neurons and cerebral organoids vs isogenic controls
Human Alzheimer’s disease (AD) brains and transgenic AD mouse models manifest hyperexcitability. This aberrant electrical activity is caused by synaptic dysfunction that represents the major pathophysiological correlate of cognitive decline. However, the underlying mechanism for this excessive excitability remains incompletely understood. To investigate the basis for the hyperactivity, we performed electrophysiological and immunofluorescence studies on hiPSC-derived cerebrocortical neuronal cultures and cerebral organoids bearing AD-related mutations in presenilin-1 or amyloid precursor protein vs. isogenic gene corrected controls. In the AD hiPSC-derived neurons/organoids, we found increased excitatory bursting activity, which could be explained in part by a decrease in neurite length. AD hiPSC-derived neurons also displayed increased sodium current density and increased excitatory and decreased inhibitory synaptic activity. Our findings establish hiPSC-derived AD neuronal cultures and organoids as a relevant model of early AD pathophysiology and provide mechanistic insight into the observed hyperexcitability.
- 29 November 2019
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 8
Open AccessMechanisms of hyperexcitability in Alzheimer’s disease hiPSC-derived neurons and cerebral organoids vs isogenic controls
Human Alzheimer’s disease (AD) brains and transgenic AD mouse models manifest hyperexcitability. This aberrant electrical activity is caused by synaptic dysfunction that represents the major pathophysiological correlate of cognitive decline. However, the underlying mechanism for this excessive excitability remains incompletely understood. To investigate the basis for the hyperactivity, we performed electrophysiological and immunofluorescence studies on hiPSC-derived cerebrocortical neuronal cultures and cerebral organoids bearing AD-related mutations in presenilin-1 or amyloid precursor protein vs. isogenic gene corrected controls. In the AD hiPSC-derived neurons/organoids, we found increased excitatory bursting activity, which could be explained in part by a decrease in neurite length. AD hiPSC-derived neurons also displayed increased sodium current density and increased excitatory and decreased inhibitory synaptic activity. Our findings establish hiPSC-derived AD neuronal cultures and organoids as a relevant model of early AD pathophysiology and provide mechanistic insight into the observed hyperexcitability.
- 19 November 2019
- Published by H1 Connect
Faculty Opinions recommendation of Clearance by Microglia Depends on Packaging of Phagosomes into a Unique Cellular Compartment.
Emerging evidence suggests that microglia are critical players in many neurodegenerative diseases. These resident brain innate immune cells can subserve anti-inflammatory or pro-inflammatory functions, and their pro-inflammatory activity may contribute greatly to neurodegeneration in diseases like Alzheimer’s and Parkinson’s disease {1}. Therefore, understanding the mechanisms of microglial surveillance and function would help identify potential targets to control their activity and, ultimately, the severity of neurodegenerative disease symptoms. In this publication, the authors study the microglial phagocytosis pathway in zebrafish embryos. Using live imaging, they tracked microglial phagocytosis of apoptotic neurons. They discovered that trafficking of individual phagocytic vesicles terminated with fusion events. Staining the fused vesicles, the authors identified a novel organelle with a unique molecular signature, distinct from traditional autophagosomes fusing with lysosomes to form autolysosomes, as found in macroautophagy. The team termed this new organelle the ‘gastrosome’ and concluded that it is the site of lytic breakdown and recycling of phagocytosed material in microglia. The authors also identified a solute carrier, Slc37a2, in phagocytic vesicles as a key player controlling the size of the gastrosome. The absence of this carrier resulted in enlarged gastrosomes and reduced microglial surveillance and function. Future work should be aimed at identifying gastrosomes in mammalian microglia, and, specifically, in human microglia, and at investigating the role of Slc37a2 in human neurodegenerative diseases. If a similar pathway is indeed present in the human brain, then the solute carrier Slc37a2 may potentially become a therapeutic target to modulate microglial activity.
- 19 November 2019
- Published by H1 Connect
Faculty Opinions recommendation of Clearance by Microglia Depends on Packaging of Phagosomes into a Unique Cellular Compartment.
Emerging evidence suggests that microglia are critical players in many neurodegenerative diseases. These resident brain innate immune cells can subserve anti-inflammatory or pro-inflammatory functions, and their pro-inflammatory activity may contribute greatly to neurodegeneration in diseases like Alzheimer’s and Parkinson’s disease {1}. Therefore, understanding the mechanisms of microglial surveillance and function would help identify potential targets to control their activity and, ultimately, the severity of neurodegenerative disease symptoms. In this publication, the authors study the microglial phagocytosis pathway in zebrafish embryos. Using live imaging, they tracked microglial phagocytosis of apoptotic neurons. They discovered that trafficking of individual phagocytic vesicles terminated with fusion events. Staining the fused vesicles, the authors identified a novel organelle with a unique molecular signature, distinct from traditional autophagosomes fusing with lysosomes to form autolysosomes, as found in macroautophagy. The team termed this new organelle the ‘gastrosome’ and concluded that it is the site of lytic breakdown and recycling of phagocytosed material in microglia. The authors also identified a solute carrier, Slc37a2, in phagocytic vesicles as a key player controlling the size of the gastrosome. The absence of this carrier resulted in enlarged gastrosomes and reduced microglial surveillance and function. Future work should be aimed at identifying gastrosomes in mammalian microglia, and, specifically, in human microglia, and at investigating the role of Slc37a2 in human neurodegenerative diseases. If a similar pathway is indeed present in the human brain, then the solute carrier Slc37a2 may potentially become a therapeutic target to modulate microglial activity.
- 29 April 2019
- Published by H1 Connect
Faculty Opinions recommendation of Physical activation of innate immunity by spiky particles.
Over the years, extensive research has been conducted to understand the biochemical basis for immune system-pathogen interaction. In this paper, the authors address another fundamental question, asking if physical cues on microbe surfaces play a role in immune system activation. Using titanium dioxide nanoparticles to simulate the spiky features of the bacterial surface (such as flagella and pili), the authors show that these morphological features play a role in stimulating/activating the immune system. For example, the authors demonstrate that spiky particles activate the inflammasome in dendritic cells, and this contributes to CD4+ and CD8+ T-cell activation. Moreover, the authors used the nanoparticles as vaccine adjuvants and show a significant increase in activation of adaptive immunity. This activation translates into enhanced survival of mice after high dose infection with influenza virus, which normally results in death. The authors suggest that this type of interaction can be utilized as a potential preventative treatment against infection. In the future, it will be important to elucidate the effect of the physical spikes of the bacterial surface on the integrity of immune cell membranes to see if this plays a role in the observed effects.
- 29 April 2019
- Published by H1 Connect
Faculty Opinions recommendation of Physical activation of innate immunity by spiky particles.
Over the years, extensive research has been conducted to understand the biochemical basis for immune system-pathogen interaction. In this paper, the authors address another fundamental question, asking if physical cues on microbe surfaces play a role in immune system activation. Using titanium dioxide nanoparticles to simulate the spiky features of the bacterial surface (such as flagella and pili), the authors show that these morphological features play a role in stimulating/activating the immune system. For example, the authors demonstrate that spiky particles activate the inflammasome in dendritic cells, and this contributes to CD4+ and CD8+ T-cell activation. Moreover, the authors used the nanoparticles as vaccine adjuvants and show a significant increase in activation of adaptive immunity. This activation translates into enhanced survival of mice after high dose infection with influenza virus, which normally results in death. The authors suggest that this type of interaction can be utilized as a potential preventative treatment against infection. In the future, it will be important to elucidate the effect of the physical spikes of the bacterial surface on the integrity of immune cell membranes to see if this plays a role in the observed effects.
- 17 August 2016
- Published by H1 Connect
- Vol. 165 (4)
Faculty Opinions recommendation of Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation.
Autosomal dominant mutations in the human progranulin (GRN) gene, which cause a reduction in progranulin (PGRN) levels, contribute to the pathogenesis of familial frontotemporal lobar degeneration (FTLD), one of the most common forms of dementia in patients under 65 years old {1}. The authors demonstrate that PGRN is an inhibitor of microglia inflammatory response, and that GRN knockout results in excessive inflammation and lysosomal...
- 17 August 2016
- Published by H1 Connect
- Vol. 165 (4)
Faculty Opinions recommendation of Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation.
Autosomal dominant mutations in the human progranulin (GRN) gene, which cause a reduction in progranulin (PGRN) levels, contribute to the pathogenesis of familial frontotemporal lobar degeneration (FTLD), one of the most common forms of dementia in patients under 65 years old {1}. The authors demonstrate that PGRN is an inhibitor of microglia inflammatory response, and that GRN knockout results in excessive inflammation and lysosomal...